Impact of prior treatment on patients with relapsed multiple
myeloma treated with carfilzomib and dexamethasone vs
bortezomib and dexamethasone in the phase 3 ENDEAVOR study

J 2017

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT et. al.

Basic information

Original name

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Authors

Edition

Leukemia, London, Nature Publishing Group, 2017, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 10.023

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/leu.2016.186

UT WoS

000394058700015

Keywords in English

2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT

Abstract

V originále

The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.

Citovat

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG and M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. London: Nature Publishing Group, 2017, vol. 31, No 1, p. 115-122. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2016.186.

@article{1369191,
   author = {Moreau, P. and Joshua, D. and Chng, W.andJ. and Palumbo, A. and Goldschmidt, H. and Hájek, R. and Facon, T. and Ludwig, H. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosiñol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S. and Dimopoulos, M.A.},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1038/leu.2016.186},
   keywords = {2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study},
   url = {http://dx.doi.org/10.1038/leu.2016.186},
   volume = {31},
   year = {2017}
}

TY  - JOUR
ID  - 1369191
AU  - Moreau, P. - Joshua, D. - Chng, W.-J. - Palumbo, A. - Goldschmidt, H. - Hájek, R. - Facon, T. - Ludwig, H. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosiñol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S. - Dimopoulos, M.A.
PY  - 2017
TI  - Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
JF  - Leukemia
VL  - 31
IS  - 1
SP  - 115-122
EP  - 115-122
PB  - Nature Publishing Group
SN  - 08876924
KW  - 2ND-GENERATION PROTEASOME INHIBITOR
KW  - STEM-CELL TRANSPLANTATION
KW  - LENALIDOMIDE MAINTENANCE
KW  - RETREATMENT
UR  - http://dx.doi.org/10.1038/leu.2016.186
L2  - http://dx.doi.org/10.1038/leu.2016.186
N2  - The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
ER  -

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG and M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. \textit{Leukemia}. London: Nature Publishing Group, 2017, vol.~31, No~1, p.~115-122. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/leu.2016.186.

Detailed Information on Publication Record